[CYCCP] Cyclacel Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CYCCP

Refresh chart

Description: Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company?s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatmen

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.38 M Cash From Investing Activities10 K Cash From Operating Activities-4.9 M Gross Profit
Net Profit-4.91 M Operating Profit-5.3 M Total Assets35.36 M Total Current Assets35.02 M
Total Current Liabilities8.14 M Total Debt Total Liabilities8.33 M Total Revenue510 K
Technical Data
High 52 week6.3 Low 52 week4.21 Last close4.76 Last change0%
RSI54.18 Average true range0.19 Beta0.23 Volume
Simple moving average 20 days3.93% Simple moving average 50 days1.72% Simple moving average 200 days-2.84%
Performance Data
Performance Week3.25% Performance Month-4.38% Performance Quart-8.13% Performance Half-7.07%
Performance Year-7.68% Performance Year-to-date-17.28% Volatility daily3.1% Volatility weekly6.92%
Volatility monthly14.19% Volatility yearly49.16% Relative Volume0% Average Volume173.02
New High New Low

News

2020-05-21 09:22:40 | 3 “Strong Buy” Biotech Stocks Under $5 With Massive Upside Potential

2020-05-12 16:05:10 | Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

2020-05-05 07:00:10 | Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results

2020-04-24 16:05:10 | Cyclacel Announces Closing of $20 Million Public Offering

2020-04-21 12:59:04 | Company News for Apr 21, 2020

2020-04-21 08:27:39 | CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

2020-04-20 07:00:10 | Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

2020-04-14 12:30:10 | Cyclacel Announces Reverse Stock Split

2020-02-26 16:05:10 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-20 08:50:01 | Cyclacel CYCC to Report Q4 Earnings: What's in the Cards?

2020-02-19 07:00:10 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

2020-02-03 07:00:10 | Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference

2020-01-13 07:00:10 | Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

2020-01-06 07:00:10 | Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

2019-12-09 07:00:10 | Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

2019-11-13 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

2019-11-07 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

2019-11-06 09:00:00 | Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

2019-09-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-09 07:00:00 | Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

2019-09-04 07:00:00 | Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference   

2019-08-13 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

2019-08-11 15:46:20 | The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

2019-08-07 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

2019-07-22 07:00:00 | Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

2019-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

2019-04-01 07:00:00 | Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

2019-03-27 16:05:00 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-26 12:46:27 | Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

2019-03-25 07:00:00 | Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

2019-03-20 07:00:00 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

2019-03-13 07:00:00 | Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

2019-03-05 07:00:00 | Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

2019-02-05 07:00:00 | Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

2019-01-07 07:00:00 | Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019

2018-12-27 07:00:00 | Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

2018-11-12 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-06 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

2018-10-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

2018-10-04 07:00:00 | Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

2018-09-26 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-12 07:00:00 | Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

2018-09-10 07:00:00 | Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

2018-08-29 07:00:00 | Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference

2018-08-09 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-01 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results

2018-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results

2018-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results